Copenhagen, March 12, 2025 – The recent EU Vet KOL Group meeting at Contura’s state-of-the-art facility brought together leading equine veterinarians from across Europe to discuss the remarkable benefits and future directions of Arthramid, the revolutionary 2.5% iPAAG hydrogel product for equine joint treatment. The gathering was marked by enthusiasm and a shared commitment to advancing veterinary medicine.
A Gathering of Experts
The meeting was attended by renowned veterinarians including Marc Koene, Antonio Cruz, Edwin Enzerik, Andy Bathe, Rasmus Westgren, Florent David, Luis Lamas, Jonathan Anderson, Martin Hjorth, Aziz Tnibar, Alexandra Keller, JD Conway, and Jason Lowe. The presence of Rakesh Tailor (CEO), Ieva Ankorina-Stark (CSO), and Richard Kingston (CFO) from Contura further underscored the significance of the event and commitment of Contura to the equine health industry.
Arthramid: A Safe, Long-Term, Cost-Effective Solution
Discussions highlighted Arthramid’s unique properties, including its biocompatibility and viscoelasticity, which make it an ideal choice for long-term joint management in equine performance practice. Retrospective studies presented at the meeting demonstrated that Arthramid significantly improves joint function in horses, with minimal adverse events and sustained athletic performance.
Quality at Contura’s Facility
Participants were impressed by the quality of Contura’s facility, which adheres to GMP manufacturing standards. The factory tour showcased the meticulous processes involved in producing Arthramid, ensuring the highest level of quality and safety for veterinary use
Sharing Tips and Tricks
The meeting provided an invaluable opportunity for expert veterinarians to share tips and tricks for successful case management and selection, including dosing regimens for different joints. Recommendations included using ultrasound guidance for joint injections in some cases and avoiding the lateral recess when treating the fetlock to maximize the efficacy of Arthramid.
Future Research and Regulatory Collaboration
Updates on future research directions were eagerly received, with ongoing studies aimed at understanding Arthramid’s long-term effects and exploring its mechanisms of action. The company is actively working with regulators and the industry to improve education around how to obtain the product in Europe under special import licence until market approval is achieved.
Conclusion
The EU Vet KOL Group meeting was a resounding success, fostering collaboration and innovation in equine veterinary medicine. The excitement and shared commitment to advancing Arthramid’s application in equine joint treatment were palpable, promising a bright future for this groundbreaking product.
For more information, please contact: Jason Lowe Managing Director & Chief Veterinary Officer Contura Jason.Lowe@conturavet.com
